TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 20 - \<65 years,~* body mass index (BMI) ≥ 24 kg/m2,~* HbA1c ≥ 7% (53mmol/mol).~* diabetes antibodies (-)~* diagnosed with T2D within the previous 3 months~Exclusion Criteria:~* anti-diabetic drugs or diet therapy before participation~* pancreatitis~* coronary artery disease~* liver function impairment~* renal function impairment~* intestinal surgery~* chronic hypoxic diseases (emphysema and cor pulmonale)~* infectious disease~* hematological disease~* systemic inflammatory disease~* cancer~* pregnant, possibly pregnant~* ingesting agents known to influence glucose or lipid metabolism

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- exenatide group (Type: EXPERIMENTAL): The drug-naïve, overweight or obese patients with newly diagnosed T2D
- metformin group (Type: ACTIVE_COMPARATOR): The drug-naïve, overweight or obese patients with newly diagnosed T2D

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Melatonin and the Metabolic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 30-79 years.~2. Diagnosed with metabolic syndrome according to AdenosineTriphosphate-III criteria.~3. Availability for six months after enrolling in the study.~Exclusion Criteria:~1. Inability to understand informed consent and to cooperate with study procedures.~2. Supplemental intake of melatonin.~3. Current smoking.~4. Current use of calcium channel blockers.~5. Current, planned, or recent (12 months) participation in another clinical trial.~6. Women who are pregnant, breast-feeding, attempting conception, or planning to attempt conception over the next 6 months.~7. Presence of any of the following diagnosed health conditions:~   * Active malignancy other than nonmelanoma skin cancer (current therapy for this malignancy,diagnosis within five years of enrollment, recurrence within five years of enrollment, or metastasis)~  * Uncontrolled hypothyroidism or hyperthyroidism~  * Recent (\< 1 year ago) history of heart attack, bypass surgery, angioplasty, or stroke~  * Heart failure (New York Heart Association functional class 3 or 4)~  * On renal dialysis~  * Immunosuppressive therapy (systemic corticosteroids, azathioprine, methotrexate, cyclophosphamide,~  * etc.) or an immunodeficiency syndrome~  * Narcotic or alcohol dependence~  * Obstructive sleep apnea (OSA) , defined either by previous diagnosis (with or without use of nasal CPAP), or by a score of 0.80 or higher on the MAP (Multivariate Apnea Prediction), a validated screening algorithm with high positive and negative predictive value for identifying OSA.~8. Shift-workers.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Melatonin (Type: EXPERIMENTAL): Melatonin 8mg one hour before bedtime for 10 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered 1 hour before bedtime for 10 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adequate complete blood counts, liver and renal function~* 12-lead electrocardiogram (ECG) within normal limits~* Female subjects of child bearing potential agreeing to use a protocol specified method of contraception~* Male subjects agreeing to use protocol specified methods of contraception~* Willing to provide written informed consent and willing to comply with study requirements~Exclusion Criteria:~* Any uncontrolled or serious disease, or any medical or surgical condition, that may interfere with participation in the clinical study and/or put the subject at significant risk~* Received an investigational agent within 90 days before the first dose of study drug or are in follow-up of another clinical study~* History of multiple drug allergies or intolerance to subcutaneous injection~* Parts A and B of the study: Used prescription medications within 14 days or 7 half-lives of administration of the first dose of study drug.~* History of meningococcal infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- ALN-CC5 (Type: ACTIVE_COMPARATOR): None
- Sterile Normal Saline (0.9% NaCl) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Having signed informed consent~* Age 18 to 75 years old~* Histologically confirmed gastric adenocarcinoma~* Unresectable recurrent or metastatic disease~* Previous neo-adjuvant or adjuvant treatment for gastric cancer, if applicable, more than 12 months~* Measurable disease according to the RECIST criteria~* Karnofsky performance status ≥60~* Life expectancy of ≥2 month~* No prior radiotherapy except radiotherapy at non-target lesion of the study more than 4 weeks~* ALT and AST\<2.5 times ULN (≤5 times ULN in patients with liver metastases)~* Serum albumin level ≥3.0g/dL~* Serum AKP \< 2.5 times ULN~* Serum creatinine \<1.5mg/dL~* Bilirubin level \< 1.5mg/dL~* Serum creatinine \<1.5 times ULN~* WBC\>3,000/mm3, absolute neutrophil count ≥2000/mm3, platelet\>100,000/mm3, Hb\>9g/dl~Exclusion Criteria:~* Brain metastasis (known or suspected)~* Previous systemic therapy for metastatic gastric cancer~* Inability to take oral medication~* Previous EGFR pathway-targeting therapy~* Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry~* Heart failure, coronary artery disease, myocardial infarction within the last 6 months~* Known allergy to any study treatment~* Pregnancy or lactation period~* Any investigational agent within the past 28 days~* Other previous malignancy within 5 year, except non-melanoma skin cancer~* Previous adjuvant therapy with capecitabine+platinum~* Pre-existing neuropathy\>grade 1~* Legal incapacity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- C225+Chemotherapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female COPD patients aged ≥ 40 years~* Current smokers or ex-smokers~* FEV1\<50% predicted (FEV1/FVC \<0,7)~* at least 1 documented exacerbations in the last 12 Mo~Exclusion Criteria:~* Pregnant or lactating women and all women physiologically capable of becoming pregnant~* Diagnosis of asthma, history of allergic rhinitis or atopy~* Patients treated for exacerbations 1 Mo prior to screening~* Patients treated with non-cardioselective β-blockers~* Patients treated with long-acting antihistamines~* Known respiratory disorders other than COPD~* Patients who have clinically significant cardiovascular condition

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BDP/FF/GB (Type: EXPERIMENTAL): CHF 5993 pMDI 100/6/12.5 mcg 2 inhalations b.i.d
- Tiotropium (Type: ACTIVE_COMPARATOR): Tiotropium bromide 18 mcg
- BDP/FF + Tiotropium (Type: ACTIVE_COMPARATOR): BDP/FF pMDI 100/6/12.5 mcg 2 inhalations b.i.d and Tiotropium 18 mcg daily~BDP/FF/GB versus BDP/FF + Tiotropium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Compartment Psoas Block Efficacy and Safety

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~-proximal femur fracture~Exclusion Criteria:~* pregnancy and lactation~* history of opiate addiction~* traumatic brain injury~* acute cerebrovascular accident~* chronic heart failure (New York Heart Association Functional Classification, NYHA, class III-IV)~* respiratory failure~* renal failure with decreased creatinine clearance less than 30 ml / min / 1.73 m2~* hepatic insufficiency class C according to Child-Pugh).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Patients in group 1 underwent catheterization of the lumbar plexus from the posterior access on admission to the hospital and began analgesia with bupivacaine 0.125% 6-8 ml / h. Intraoperative anaesthesia was provided with a bupivacaine bolus of 0.5% 200 mg in a lumbar catheter and a sciatic nerve block with 1.5% 450 mg of lidocaine. Postoperative analgesia was provided by an elongated lumbar plexus block with bupivacaine 0.125% 6-8 ml / h.
- Group 2 (Type: NO_INTERVENTION): Patients in group 2 underwent intraoperative spinal anaesthesia at the level of L3-L4 with hyperbaric bupivacaine at a dose of 10-15 mg.
- Group 3 (Type: NO_INTERVENTION): Group 3 patients underwent general inhalation anaesthesia with sevoflurane with a constant infusion of fentanyl for analgesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Helicobacter Pylori Eradication With a New Sequential Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Presence of active H. pylori infection~* Age \>18 years~Exclusion Criteria:~* Allergy to drug administered~* Liver or kidney failure~* Pregnancy~* Previous treatment for H. pylori infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients both sexes~* Age between 30 and 50 years~* Metabolic Syndrome according to the IDF criteria~* Waist circumference~* Man ≥90 cm~* Woman ≥80 cm~* And two of the following criteria:~* High density lipoprotein~* Man ≤40 mg/dL~* Woman ≤50 mg/dL~* Fasting glucose ≥100 mg/dL~* Triglycerides ≥150 mg/dL~* Blood pressure ≥130/85 mmHg~* Informed consent signed~Exclusion Criteria:~* Women with confirmed or suspected pregnancy~* Women under lactation and/or puerperium~* Hypersensibility to resveratrol~* Physical impossibility for taking pills~* Known uncontrolled renal, hepatic, heart or thyroid diseased~* Previous treatment for the metabolic syndrome components~* Body Mass Index ≥39.9 kg/m2~* Fasting glucose ≥126 mg/dL~* Triglycerides ≥500 mg/dL~* Total cholesterol ≥240 mg/dL~* Low density lipoprotein (c-LDL) ≥190 mg/dL~* Blood Pressure ≥140/90 mmHg

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Resveratrol (Type: EXPERIMENTAL): Resveratrol capsules, 500 mg, three times per day before meals during 90 days
- Placebo (Type: PLACEBO_COMPARATOR): Calcined magnesia capsules, 500 mg, three times per day before meals during 90 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~In accordance with the SPC. Most important criteria:~* Histology or cytology proven inoperable, locally advanced,metastatic or recurrent (stage IIIB/IV) NSCLC other than predominantly squamous cell histology~* First-line treatment is indicated~* No previous treatment with Bevacizumab~Exclusion Criteria:~In accordance with the SPC. Most important criteria:~* Hypersensitivity to the active ingredient or to any of the excipients~* Hypersensitivity to products derived from Chinese hamster ovary (CHO) cells or to other recombinant human or humanized antibodies~* Pregnancy~* Bevacizumab is contraindicated in the presence of untreated central nervous system metastases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab (Type: None): Participants with advanced (stage IIIB/IV) NSCLC other than predominantly squamous cell histology receiving Bevacizumab in accordance with the summary product characteristics (SPC) is observed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, ≥ 18 years of age~* Subject has been receiving regular apheresis for LDL-C lowering for at least 3 months immediately prior to lipid screening and has a treatment goal of LDL-C \< 100 mg/dL (2.6 mmol/L), and has been receiving LDL-C apheresis during the last ≥ 4 weeks prior to lipid screening at regular QW or Q2W schedule and with no changes in apheresis type~* Subject is receiving lipid-lowering pharmacological background therapy which includes a high-intensity statin dose (moderate-intensity statin dose with attestation that a higher dose is not appropriate for the subject) unless the subject has a history of statin intolerance~* Lipid-lowering therapy status (ie, any therapy for lowering lipids, including apheresis type and frequency) must be unchanged for ≥ 4 weeks prior to LDL-C screening~* Pre-apheresis LDL-C is ≥ 100 mg/dL (≥ 2.6 mmol/L) and ≤ 190 mg/dL (≤ 4.9 mmol/L) at screening~* Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L) at screening.~Exclusion criteria:~* Known homozygous familial hypercholesterolemia~* Missing any apheresis session is medically contraindicated or inappropriate~* Stopping apheresis would be inappropriate in the opinion of the investigator even if LDL-C is controlled to \< 100 mg/dL with other therapies~* Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization.~* Uncontrolled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Evolocumab (Type: EXPERIMENTAL): Participants received 140 mg evolocumab every 2 weeks (Q2W) administered by subcutaneous injection for 6 weeks during the primary period of the study. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.
- Low Density Lipoprotein Cholesterol (LDL-C) Apheresis (Type: ACTIVE_COMPARATOR): Participants continued apheresis at the same schedule, every week (QW) or every two weeks (Q2W), as prior to study entry, for the first 6 weeks. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Fluticasone Versus Placebo at the Onset of a Cold for Children With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* (1) Children aged 1-6 years,~* (2) they had at least 2 documented episodes of URTI-induced asthma requiring systemic (i.e., oral, intravenous, or intramuscular) corticosteroids in the previous 12 months or 1 episode in the previous 6 months,~* (3) no intercurrent symptoms (i.e., cough, wheezing, or observed dyspnea) documented for at least 7 days between wheezing episodes,~* (4) no suspicion of allergy to pollen or perennial allergens, and~* (5) caregivers have a good understanding of French or English~Exclusion Criteria:~* (a) other chronic diseases such as cystic fibrosis, bronchopulmonary dysplasia, cardiac disease, kidney disease, gastro-oesophageal reflux requiring treatment,~* (b) intake, in the 21 days preceding randomization, of inhaled, nasal, or oral corticosteroids, leukotriene antagonists, cromolyn, nedocromyl, or ketotifen, -(c) prior intubation for an asthma exacerbation.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 6 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, ages \>18~* Fasting triglyceride ≥500 mg/dL and ≤2000 mg/dL~* Provide written informed consent and authorization for protected health information disclosure~Exclusion Criteria:~* Women who are pregnant or lactating, or planning to become pregnant~* Use of non-statin lipid-altering drugs which cannot be stopped including fibrates, niacin, fish oil and other products containing omega-3 fatty acids or other dietary supplements with potential lipid-altering effects~* History of pancreatitis~* History of bariatric surgery or currently on weight loss drugs~* Uncontrolled hypertension (BP \> 160/100)~* HIV infection or on treatment with HIV-protease inhibitors, cyclophosphamide,or isotretinoin~* Consumption of more than 2 alcoholic beverages per day~* History of cancers (except if been disease free for \>5 years OR history was basal or squamous cell skin cancer)~* Participation in another clinical trial involving an investigational agent in the last 30 days~* Other parameters will be assessed at the study center to ensure eligibility for this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- AMR101 (ethyl icosapentate) - 2 g/day (Type: EXPERIMENTAL): None
- AMR101 (ethyl icosapentate) - 4 g/day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must have endoscopically confirmed erosive esophagitis as defined by the Los Angeles (LA) Classification Grading System (A-D).~Exclusion Criteria:~* Subject has a positive Campylobacter-like organisms (CLO) test for Helicobacter (H.) pylori.~* Use of prescription or non-prescription proton pump inhibitors (PPIs), histamine (H2) receptor antagonists or sucralfate, drugs with significant anticholinergic effects, misoprostol or prokinetics~* Use of antacids \[except for study supplied Gelusil®\]~* Need for continuous anticoagulant therapy (Blood Thinners)~* Endoscopic Barrett's esophagus and/or definite dysplastic changes in the esophagus~* History of dilatation of esophageal strictures, other than Schatzki's ring (a ring of mucosal tissue near the lower esophageal sphincter)~* Current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory condition~* History of gastric, duodenal or esophageal surgery except simple oversew of an ulcer~* Acute upper gastrointestinal (UGI) hemorrhage within 4 weeks of the Screening endoscopy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexlansoprazole MR 60 mg QD (Type: EXPERIMENTAL): None
- Dexlansoprazole MR 90 mg QD (Type: EXPERIMENTAL): None
- Lansoprazole 30 mg QD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete